The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy

The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy

Abstract Background The gut microbiome is implicated as a marker of response to  immune checkpoint inhibitors (ICI) based on preclinical mouse models and preliminary observations in limited patient series. Furthermore, early studies suggest faecal microbial transfer may have therapeutic potential, c...

Full description

Bibliographic Details
Main Authors: Nicola A. Thompson, Grant D. Stewart, Sarah J. Welsh, Gary J. Doherty, Matthew J. Robinson, B. Anne Neville, Kevin Vervier, Simon R. Harris, David J. Adams, Katy Dalchau, David Bruce, Nikolaos Demiris, Trevor D. Lawley, Pippa G. Corrie
Format: Article
Language:English
Published: BMC 2022-01-01
Series:BMC Cancer
Subjects:
Microbiome
Immunotherapy
Melanoma
Renal cancer
Non-small cell lung cancer
Biomarker
Online Access:https://doi.org/10.1186/s12885-021-09156-x

Internet

https://doi.org/10.1186/s12885-021-09156-x

Similar Items